US$45.8m in Appendix 4C vs forecast US$46.6m ... I'd say pretty much on expectation
With not much really happening in the last quarter, the upcoming quarter is looking to provide some much needed clarity around the source of funding for MSB.
Does it continue to raise capital from the market (AU or US) and extend the negotiation period with MNK (are they waiting for the sale of their generics business?) or does MNK join the party in the next few months?
MNK probably can't wait too long, as the aGVHD phase 3 will read out at the end of the year/ early next year ... so there is at least somewhat of a hard deadline in place.
Mesoblast cash forecast, page-11
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |